Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Prophase Labs ( (PRPH) ) is now available.
On June 26, 2025, ProPhase Labs announced that it received a 180-day extension from Nasdaq to meet the minimum bid price requirement of $1.00 per share, following an initial period ending on June 24, 2025. This extension allows the company until December 22, 2025, to regain compliance, failing which its stock may face delisting. The company is actively monitoring its stock price and exploring options to meet the requirement, although there is no assurance of compliance within the extended period. This development does not impact ProPhase Labs’ business operations or reporting obligations.
Spark’s Take on PRPH Stock
According to Spark, TipRanks’ AI Analyst, PRPH is a Underperform.
The overall stock score is primarily influenced by Prophase Labs’ significant financial challenges, including negative equity and cash flow issues. Although there are potential growth opportunities discussed in recent earnings calls, the stock’s technical indicators and valuation metrics remain weak, contributing to a low overall score.
To see Spark’s full report on PRPH stock, click here.
More about Prophase Labs
ProPhase Labs Inc. is a next-generation biotech, genomics, and consumer products company focused on revolutionizing healthcare through Whole Genome Sequencing solutions, diagnostic development, and direct-to-consumer marketing of OTC dietary supplements. The company aims to build a healthier world through innovation and actionable insight, with a focus on health and wellness solutions.
Average Trading Volume: 2,733,292
Technical Sentiment Signal: Sell
Current Market Cap: $14.5M
For an in-depth examination of PRPH stock, go to TipRanks’ Overview page.